Insmed Incorporated (INSM)

Insmed, Inc.'s stock price has experienced significant positive movement, trending up by 6.46% and surging by 78% over the past six months. The FDA approval of brensocatib (Brinsupri) in the United States in August 2025, followed by its approval in the European Union in November 2025, was a primary catalyst. Strong demand for ARIKAYCE across all marketed regions, leading to double-digit year-over-year growth and raised full-year revenue guidance in November 2025, further boosted investor confidence. Positive topline results from the Phase 3 ASPEN study of brensocatib in bronchiectasis in 2024 were also a defining moment for the company. In 2024, Insmed also raised over $1.2 billion in equity and debt financing to support its pipeline and expansion, including a public offering in May 2024.

There is no readily available public information indicating demand seasonality for Insmed, Inc.'s products and services. Analysis of historical data for seasonality is not available.

Insmed, Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, operating within the Healthcare sector, specifically in Biotechnology & Drugs. Its primary focus areas include pulmonary and inflammatory conditions, as well as other rare diseases. Insmed's major commercial product is ARIKAYCE, an inhaled antibiotic approved for the treatment of Mycobacterium avium complex (MAC) lung disease. The company's pipeline includes Brinsupri (brensocatib), an oral drug approved for non-cystic fibrosis bronchiectasis (NCFB), treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and INS1201, an early-stage gene therapy for Duchenne muscular dystrophy. Insmed also engages in preclinical research programs utilizing technologies such as gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Insmed maintains a global presence with offices and research centers located across the United States, Europe, and Japan. Its key commercial product, ARIKAYCE, is approved and marketed in these regions.

Insmed has cultivated a strong brand reputation, evidenced by its consistent recognition as a top science-focused employer for multiple years. The positive topline results from the Phase 3 ASPEN study of brensocatib in bronchiectasis in 2024 significantly enhanced the company's standing in the biopharmaceutical industry. The subsequent FDA approval of Brinsupri in August 2025 and its EU approval in November 2025 further solidified Insmed's reputation as an innovator in addressing unmet medical needs for serious diseases.

Insmed's ownership is predominantly held by institutional investors, who collectively hold a substantial portion of the company's outstanding shares, approximately 84.11% to 98.57%. Major institutional owners include JPMorgan Chase & Co, Vanguard Group Inc, Darwin Global Management, Ltd., BlackRock, Inc., Fmr Llc, Baker Bros. Advisors Lp, State Street Corp, Capital International Investors, Artisan Partners Limited Partnership, and Rtw Investments, Lp. Richard S. Kollender is noted as a significant individual shareholder, owning 10.17% of the company's shares. Insiders, including individual investors, hold a smaller percentage, around 0.76% to 17.40%.